Johnson & Johnson (JNJ)
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson announces $2 billion investment to boost U.S. manufacturing as tariffs loom
Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump's administration.
Can J&J Navigate Stelara, Talc Suits, Tariff & Other Headwinds?
J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.
2 unstoppable dividend stocks to buy now
For long-term investors, dividend-paying companies remain a key factor as they provide both income and stability.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Is Johnson & Johnson (JNJ) Up 7.2% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Bet on JNJ & Hold on to Apple to Grow Your Retirement Fund Stress-Free
JNJ offers resilience and income, while Apple fuels long-term growth???ideal picks for a stress-free retirement portfolio.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Johnson & Johnson Stock Still Has Room To Run
On July 16, Johnson & Johnson did what I've been waiting for, namely, its revenue and EPS beat Wall Street analysts' expectations by a wide margin. The 42.7% year-over-year decline in sales of its "outdated" superstar Stelara was more than offset by the strong performance of its oncology franchise. Sales of Erleada, which is becoming the "gold standard" in prostate cancer treatment, reached $908 million, up 17.8% quarter-over-quarter.
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
JNJ edges out AZN following Q2 results with raised guidance, stronger estimate revisions and a more attractive valuation.
